Naim Pamuk1, Tolga Akkan2, Murat Dağdeviren2, Arzu Or Koca2, Esin Beyan1, Derun Taner Ertuğrul2, Mustafa Altay2. 1. University of Health Sciences Turkey, Keçiören Education and Research Hospital, Department of Internal Medicine, Ankara, Turkey. 2. University of Health Sciences Turkey, Keçiören Education and Research Hospital, Department of Endocrinology and Metabolism, Ankara, Turkey.
Abstract
OBJECTIVE: The aim of the present study was to evaluate whether arterial stiffness is affected in the patients with hypoparathyroidism through pulse wave analysis (PWA). SUBJECTS AND METHODS: Sixty-three patients diagnosed with hypoparathyroidism and sixty volunteers were evaluated for the study. When 21 patients were excluded in the hypoparathyroidism group due to exclusion criteria, the research continued with 42 patients and 60 volunteers who are similar to the patients in terms of age, gender and body mass index (BMI). Fasting plasma glucose after 10 hours of fasting, creatinine, thyroid stimulating hormone (TSH), free thyroxine (fT4), albumin, calcium, phosphorus, magnesium, 25-OH vitamin D, parathormone (PTH) and urine calcium results in 24-hour urine for the patients in the hypoparathyroidism group were recorded. Evaluation of arterial stiffness was performed by Mobil-O-Graph 24h PWA device. RESULTS: Systolic blood pressure (SBP) (p = 0.01), diastolic blood pressure (DBP) (p = 0.005), mean blood pressure (p = 0.009), central SBP (p = 0.004), central DBP (p = 0.01) and pulse wave velocity (PWV) (p = 0.02) were found higher in the hypoparathyroidism group. A positive correlation was detected between phosphorus level and SBP [(p = 0.03. r = 0.327)], central SBP [(p = 0.04, r = 0.324)] and PWV [(p = 0.003, r = 0.449)]. We detected that age and serum phosphorus levels were independent predictor variables for PWV (B = 0.014, p < 0.001 and B = 0.035, p < 0.001, respectively). CONCLUSION: We detected that hypoparathyroidism causes an increase in blood pressure and arterial stiffness. The most significant determinant factors were detected as advanced age and hyperphosphatemia. The patients diagnosed with hypoparathyroidism should be closely monitored and treatment planning should include to prevent the patients from hyperphosphatemia.
OBJECTIVE: The aim of the present study was to evaluate whether arterial stiffness is affected in the patients with hypoparathyroidism through pulse wave analysis (PWA). SUBJECTS AND METHODS: Sixty-three patients diagnosed with hypoparathyroidism and sixty volunteers were evaluated for the study. When 21 patients were excluded in the hypoparathyroidism group due to exclusion criteria, the research continued with 42 patients and 60 volunteers who are similar to the patients in terms of age, gender and body mass index (BMI). Fasting plasma glucose after 10 hours of fasting, creatinine, thyroid stimulating hormone (TSH), free thyroxine (fT4), albumin, calcium, phosphorus, magnesium, 25-OH vitamin D, parathormone (PTH) and urine calcium results in 24-hour urine for the patients in the hypoparathyroidism group were recorded. Evaluation of arterial stiffness was performed by Mobil-O-Graph 24h PWA device. RESULTS: Systolic blood pressure (SBP) (p = 0.01), diastolic blood pressure (DBP) (p = 0.005), mean blood pressure (p = 0.009), central SBP (p = 0.004), central DBP (p = 0.01) and pulse wave velocity (PWV) (p = 0.02) were found higher in the hypoparathyroidism group. A positive correlation was detected between phosphorus level and SBP [(p = 0.03. r = 0.327)], central SBP [(p = 0.04, r = 0.324)] and PWV [(p = 0.003, r = 0.449)]. We detected that age and serum phosphorus levels were independent predictor variables for PWV (B = 0.014, p < 0.001 and B = 0.035, p < 0.001, respectively). CONCLUSION: We detected that hypoparathyroidism causes an increase in blood pressure and arterial stiffness. The most significant determinant factors were detected as advanced age and hyperphosphatemia. The patients diagnosed with hypoparathyroidism should be closely monitored and treatment planning should include to prevent the patients from hyperphosphatemia.
Authors: S Polonine; R G de Santa Rosa; M L F Farias; M I Garcia; C P Gomes; I Gottlieb; M Madeira Journal: J Endocrinol Invest Date: 2022-03-02 Impact factor: 4.256
Authors: Andrea Grillo; Vincenzo Barbato; Roberta Maria Antonello; Marco Fabio Cola; Gianfranco Parati; Paolo Salvi; Bruno Fabris; Stella Bernardi Journal: J Clin Med Date: 2022-06-01 Impact factor: 4.964
Authors: Katerina Sarapis; Colleen J Thomas; Johanna Hoskin; Elena S George; Wolfgang Marx; Hannah L Mayr; Greg Kennedy; Andrew Pipingas; Jane C Willcox; Luke A Prendergast; Catherine Itsiopoulos; George Moschonis Journal: Nutrients Date: 2020-07-29 Impact factor: 5.717